Items where authors include "Dryden, M"

Article

Noviello, S, Corey, GR, Holland, TL et al. (9 more authors) (2020) A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. Journal of Medical Microbiology. 001177. ISSN 0022-2615

Corey, GR, Wilcox, MH orcid.org/0000-0002-4565-2868, Gonzalez, J et al. (6 more authors) (2019) Ceftaroline Fosamil Therapy in Patients With Acute Bacterial Skin and Skin Structure Infections With Systemic Inflammatory Signs: A Retrospective Dose Comparison Across Three Pivotal Trials. International Journal of Antimicrobial Agents, 53 (6). pp. 830-837. ISSN 0924-8579

Huang, DB, Magnet, S, De Angelis, S et al. (6 more authors) (2019) Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. Diagnostic Microbiology and Infectious Disease, 93 (2). ISSN 0732-8893

Huang, DB, Corey, GR, Holland, TL et al. (8 more authors) (2018) Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. International Journal of Antimicrobial Agents, 52 (2). pp. 233-240. ISSN 0924-8579

Holland, TL, O'Riordan, W, McManus, A et al. (12 more authors) (2018) A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrobial Agents and Chemotherapy, 62 (5). e02580-17. ISSN 0066-4804

Huang, DB, O'Riordan, W, Overcash, JS et al. (10 more authors) (2018) A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. Clinical Infectious Diseases, 66 (8). pp. 1222-1229. ISSN 1058-4838

Huang, DB, File, TM, Dryden, M et al. (3 more authors) (2018) Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. Diagnostic Microbiology and Infectious Disease, 90 (4). pp. 329-334. ISSN 0732-8893

Huang, DB, Duncan, LR, Flamm, RK et al. (5 more authors) (2018) The Effect of Pulmonary Surfactant on the In Vitro Activity of Iclaprim Against Common Respiratory Bacterial Pathogens. Diagnostic Microbiology and Infectious Disease, 90 (1). pp. 64-66. ISSN 0732-8893

Huang, DB, File, TM, Torres, A et al. (5 more authors) (2017) A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens. Clinical Therapeutics, 39 (8). pp. 1706-1718. ISSN 0149-2918

Cooke, J, Stephens, P, Ashiru-Oredope, D et al. (13 more authors) (2015) Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures. Journal of Antimicrobial Chemotherapy, 70 (1). pp. 279-285. ISSN 0305-7453